-
Start Preamble
Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 19, 2007, Dade Behring Inc., 100 GBC Drive, MS514, Post Office Box 6101, Attention: RA/QS, Newark, Delaware 19714-6101, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:
Drug Schedule Tetrahydrocannabinols (7370) I Benzoylecgonine (9180) II Morphine (9300) II The company plans to produce the listed controlled substances in bulk to be used in the manufacture of reagents and drug calibrator/controls for DEA exempt products.
Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 4, 2007.
Start SignatureDated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E7-12949 Filed 7-2-07; 8:45 am]
BILLING CODE 4410-09-P
Document Information
- Published:
- 07/03/2007
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Document Number:
- E7-12949
- Pages:
- 36481-36481 (1 pages)
- PDF File:
- e7-12949.pdf